UBC Faculty Research and Publications

Developing a new generation of breast cancer clinical gene expression tests Kos, Zuzana; Nielsen, Torsten O Jul 7, 2014

Your browser doesn't seem to have a PDF viewer, please download the PDF to view this item.

Item Metadata


52383-13058_2014_Article_3418.pdf [ 275.38kB ]
JSON: 52383-1.0132577.json
JSON-LD: 52383-1.0132577-ld.json
RDF/XML (Pretty): 52383-1.0132577-rdf.xml
RDF/JSON: 52383-1.0132577-rdf.json
Turtle: 52383-1.0132577-turtle.txt
N-Triples: 52383-1.0132577-rdf-ntriples.txt
Original Record: 52383-1.0132577-source.json
Full Text

Full Text

EDITORIALDeveloping a new generaem/When treatment is based solely on clinicopathological riskfactors, many women with estrogen receptor-positive/women who experienced no distant recurrences at 10 years.Kos and Nielsen Breast Cancer Research 2014, 16:103http://breast-cancer-research.com/content/16/4/103Vancouver, BC V6H 3Z6, CanadaFull list of author information is available at the end of the articletherapy-treated population may identify women notneeding extended endocrine therapy, consistent with the(ER /HER2 ) tumors are overtreated – subjected tomorbidity from cytotoxic chemotherapy for negligiblebenefit. Identifying patients safely treated by endocrine* Correspondence: torsten@mail.ubc.ca2Genetic Pathology Evaluation Centre, Department of Pathology andLaboratory Medicine, University of British Columbia, 2660 Oak Street,ficult to infer, although the 100% metastasis-free survivalin both the fluorouracil–epirubicin–cyclophosphamide andthe fluorouracil–epirubicin–cyclophosphamide–paclitaxelrandomized arms does imply no benefit from addingpaclitaxel.The authors speculate that the EPclin low-risk group(recurrence-free at 10 years) in this 5-year endocrinehuman epidermal growth factor receptor 2-negative+ −As the whole of this cohort received chemotherapy, theclinical utility of this finding (to avoid chemotherapy) is dif-When treatment decisions are based purely onclinicopathological factors, many women with estrogenreceptor-positive/human epidermal growth factorreceptor 2-negative cancers are overtreated. Geneexpression profiles are valuable clinical tools that stratifythe recurrence risk to identify patients most likely tobenefit from adjuvant systemic therapies. Buildingupon greater understanding of tumor biology andmore rigorous approaches to validation (includingindependent studies with a high level of evidence),several second-generation multigene tests have beendeveloped. In the previous issue, Martin and colleaguesreport the third clinical validation study for EndoPredict,a distributed assay to assess risk of distant recurrencesin estrogen receptor-positive/human epidermal growthfactor receptor 2-negative women. The authorsconfirm the assay’s independent prognostic value inpremenopausal and postmenopausal, node-positivewomen treated with contemporary chemotherapyfollowed by endocrine therapy. EndoPredict did not,however, predict benefit from adding paclitaxel.Predictive signatures for selecting among chemotherapyregimens remain an area needing further development.Abstracttherapy alone has driven the development of prognosticgene expression assays.clinical gene expression tZuzana Kos1 and Torsten O Nielsen2*See related research by Martin et al., http://breast-cancer-research.co© Kos and Nielsen; licensee BioMed CenCreative Commons Attribution License (http:/distribution, and reproduction in any mediumDomain Dedication waiver (http://creativecomarticle, unless otherwise stated.2014tion of breast cancerstscontent/16/2/R38In the previous issue, Martin and colleagues describethe third clinical validation of EndoPredict (EP; SividonDiagnostics GmbH, Cologne, Germany) [1], a second-generation multigene test trained to predict distant recur-rence in ER+/HER2− tumors, and by extension the needfor adjuvant chemotherapy. EP was previously validated inprospective–retrospective analyses of endocrine-treatedpostmenopausal ER+/HER2− breast cancer patients intwo clinical trials (ABCSG-6 and ABCSG-8) [2].Genomic-based assays developed from complex, high-dimensional data are susceptible to overfitting. Clinicalvalidation must be performed in entirely independentdatasets using predefined, locked-down classifier algo-rithms and analysis plans. Martin and colleagues’ studyexemplifies the rigor required by Simon and colleagues fora formal prospective–retrospective study to contributeto generating level IB evidence [3]. The authors presentEP validation results in ER+/HER2− patients from theGEICAM/9906 clinical trial of node-positive womentreated with contemporary chemotherapy. The prognosticability of EP remains robust in this higher risk group, iden-tifying a 10-year metastatic rate of 7% in the predefined EPlow-risk group (versus 30% in the high-risk group). Includ-ing tumor size and nodal status as the EPclin classifier iden-tifies a small (13%) but impressively low-risk cohort oftral Ltd. This is an Open Access article distributed under the terms of the/creativecommons.org/licenses/by/4.0), which permits unrestricted use,, provided the original work is properly credited. The Creative Commons Publicmons.org/publicdomain/zero/1.0/) applies to the data made available in thisTable 1 Overview of selected multigene signatures for breast cancerAssay;platform,clinicalmaterialTraining parameter Approval orendorsementAnalyticalvalidity:publishedassayvalidationClinicalvalidity:prognosisvalidationPredicting treatment benefit using randomized clinical trials RandomizedprospectivetrialsTamoxifen Herceptin Chemotherapyversus nochemotherapySpecificagent:anthracyclineSpecific agent:taxaneBreast CancerIndex; RT-PCR, FFPE(central)Outcome (ER+, pN0,endocrine-treated women)MGI component – biology(tumor grade related genes)H:I component – outcome(recurrence in tamoxifen-treated women)No No ATAC [13],Stockholm [17],multiplenonrandomizedtrial cohortsNoa No No No No NoEndoPredict;RT-PCR, FFPE(distributed)Outcome (distantrecurrence in endocrine-treated ER+/HER2− pN0/pN+women)CE Mark Yes [18,19] ABCSG6 [2],ABCSG8 [2],GEICAM/9906[1]No No No No GEICAM/9906 [1](failed to predictbenefit)NoIHC4; IHC,FFPE(distributed)Outcome (distantrecurrence in ER+endocrine-treated women)No No ATAC [14],TEAM [20]No No No No No NoMammaPrint;microarray,fresh andFFPE (central)Outcome (5-year metastasisrate in pN0 women)FDA (fresh): risk fordistant metastasis,<61 years, stage I andII, tumor ≤5 cm andnode-negativeNo Multiplenonrandomizedtrial cohortsincludingRASTERNo No No No No MINDACTprognosisvalidation (toreport 2015)Mammostrat;IHC, FFPE(central)Outcome (unselectedcohort of breast cancerpatients)No No NSABP-B14,NSABP-B20 [15]multiple non-randomized trialcohortsNo No NSABP-B20(±CMF) [15] (allwomen benefit– high riskbenefit themost)No No NoOncotype DX;RT-PCR, FFPE(central)Outcome (recurrence inmainly tamoxifen-treatedER+, pN0 women)NCCN, ASCO, St.Gallen (role foridentifying womenthat may benefit fromchemotherapy)Yes [21] NSABP-B14 [9],NSABP-B28 [22],SWOG8814 [23],multiple non-randomized trialcohortsNSABP-B14[24] (largestbenefit inquantitativeER high/recurrencerisk lowpatients)No NSABP-B20(±CMF) [25],SWOG8814(±CAF) [23](benefit fromchemotherapywith highrecurrence score)No NSABP-B28 [22](failed to predicta benefit)TAILORx(node-negative, toreport 2015)RxPONDER(one to threepositive nodes,recruiting)PAM50(researchbased assay);RT-PCR andmicroarray,FFPE andfresh(distributed)Biology (identification ofmajor molecular subtypes)N/A research assay No NCIC-MA5 [26],NCIC-MA12 [27],GEICAM/9906[28], multiplenonrandomizedtrial cohortsNCIC-MA12[27] (luminalsubtypepredictsbenefit)NOAH[29](HER2-enrichedbenefitsthe most)No NCIC-MA5[26] (CMF vs.CEF;epirubicinbenefit inHER2-enrichedsubtype only)GEICAM/9906,CALGB/9342 andCALGB/9840 [30](low proliferationscore predictsweekly paclitaxelbenefit)NoKosandNielsenBreastCancerResearchPage2of62014, 16:103http://breast-cancer-research.com/content/16/4/103Table 1 Overview of selected multigene signatures for breast cancer (Continued)Prosigna;nCounter,FFPE(distributed)Biology (subtype); outcome(ROR score)CE Mark, HealthCanada, FDA:prediction of 10-yearDRFS in ER+, node 0to 3, postmenopausalwomen treated withendocrine therapyYes [31] ATAC [32],ABCSG08 [33]No No No o No RxPONDER(one to threenodes,recruiting;embeddedadditionalanalysis)CAF, cyclophosphamide, doxorubicin, fluorouracil; CEF, cyclophosphamide, epirubicin, fluorouracil; CMF, cyclophosphamide, methotrexate and fluorouracil; DR , distant relapse-free survival; ER, estrogen receptor;FDA, US Food and Drug Administration; FFPE, formalin-fixed paraffin-embedded; HER2, human epidermal growth factor receptor 2; H:I, HOXB13:IL17BR; IHC, im unohistochemistry; MGI, molecular grade index; N/A,not applicable; pN0, pathological lymph node-negative; pN+, pathological lymph node-positive; ROR, risk of recurrence; RT-PCR, reverse transcription polymera chain reaction. Breast Cancer Index: bioTheranostics,San Diego, CA, USA; EndoPredict: Sividon Diagnostics GmbH, Cologne, Germany; IHC4: MammaPrint: Agendia, Amsterdam, The Netherlands; Mammostrat: Clarient, Inc. liso Viejo, CA, USA; Oncotype: Genomic Health, RedwoodCity, CA, USA; PAM50: NanoString Technologies Inc., Seatlle, WA, USA; Prosigna: NanoString Technologies Inc., Seattle, WA, USA. aNested cohort study using material fro NCIC CTG MA.17 – HOXB13/IL17BR predictive of benefitfrom extended letrozole.KosandNielsenBreastCancerResearchPage3of62014, 16:103http://breast-cancer-research.com/content/16/4/103NFSmse, AmKos and Nielsen Breast Cancer Research Page 4 of 62014, 16:103http://breast-cancer-research.com/content/16/4/103ABCSG-8 trial [4]. This promising idea must be inter-preted cautiously given that only 16 of the 74 EPclinlow-risk patients had 10-year follow-up data. Both theaTTom and ATLAS trials have shown that survival ben-efits of extended hormonal therapy become more appar-ent after year 10 [5,6].Several multigene prognostic assays have now been de-veloped for use in ER+/HER2− breast cancers. First-generation assays including MammaPrint (MammaPrint:Agendia, Amsterdam, The Netherlands) and OncotypeDX (Oncotype: Genomic Health, Redwood City, CA, USA)suffered from early methodological issues, most seriously afailure to maintain rigorous separation between trainingand validation sets, and inclusion of nonluminal and/orHER2+ tumors in their training sets, thereby allowing thesehigh-risk tumors to skew outcome-related gene selectionaway from the relevant patient group [7-9]. MammaPrintwas specifically trained around early relapse (within 5 years)in node-negative women, most having received no adjuvantsystemic therapy, and has not been shown to predict laterecurrence outside the original training-validation cohort.Oncotype DX heavily weighed the tamoxifen-only arm ofthe NSABP-B20 trial in its training set, where most recur-rences occurred within 5 years, and has diminished prog-nostic ability beyond year 5 [10].More recently, building upon biological and technicaladvances and more rigorous approaches to validation,second-generation multigene tests have been developed,including the Breast Cancer Index (BCI: bioTheranostics,San Diego, CA, USA), PAM50 (PAM50: NanoStringTechnologies Inc., Seattle, WA, USA) and EP. The BreastCancer Index combines a molecular grade index (quanti-fying tumor grade-associated genes) and a two-generatio,HOXB13:IL17BR, related to estrogen signaling [11].PAM50, unlike signatures trained around outcome, wasdeveloped as a biological classifier of the major intrinsicmolecular subtypes of breast cancer [12]. These threeassays predict both early and late recurrences [4,10,13].IHC4 and Mammostrat (Mammostrat: Clarient, Inc.,Aliso Viejo, CA, USA) immunohistochemical panels arealso prognostic in early breast cancer [14,15]. IHC4 usesstandard pathology markers (ER, progesterone receptor,HER2 and Ki67) to provide prognostic information com-parable with Oncotype DX [14]. Immunohistochemicalstaining and scoring does suffer from limited analyticalreproducibility, probably contributing to Martin and col-leagues’ identification of low Ki67 scores (<14%; a pub-lished cutoff point for good-prognosis luminal A tumors)in a surprisingly high fraction (almost three-quarters) ofthis node-positive cohort [16].Each of these gene expression and immunohistochemicalpanels identifies a good prognosis group that may notneed chemotherapy. Emerging evidence suggests that somepanels identify women at such low risk of late recurrencethat they may safely avoid extended endocrine therapy.For high-risk women, however, the question is not one ofchemotherapy versus no chemotherapy, but rather a ques-tion of which chemotherapy agent(s) will be most effectivefor which patients – a true predictive indication. In Martinand colleagues’ report, the EP score did not predict benefitfrom adding weekly paclitaxel to fluorouracil–epirubicin–cyclophosphamide chemotherapy. Outcome-trained sig-natures from nonchemotherapy populations are unlikelyto predict between chemotherapy regimens; Table 1 sum-marizes some relevant features of the referenced molecu-lar signatures, including predictive studies.What does the future hold for gene expression signa-tures? Cheaper and faster next-generation sequencinghas been touted as the pinnacle of personalized medi-cine, destined to render multigene expression assaysobsolete. However, the genetic complexity of tumors(copy number variations, chromosome-scale structuralchanges, thousands of mutations, epigenetic changesand intratumoral genetic heterogeneity) is proving evenmore complex than anticipated. Much as the increaseddetail from electron microscopy never did replace lightmicroscopy for cancer diagnosis, the broader signaturesdetected by representative gene expression profile as-says, reflecting clinically significant patterns commonacross many patients, are likely to remain relevant forimportant treatment decisions.AbbreviationsEP: EndoPredict; ER: Estrogen receptor; HER2: Human epidermal growthfactor receptor 2.Competing interestsTON reports a proprietary interest in the PAM50 assay, which has beenlicensed to Nanostring Technologies. ZK has no competing interests.Author details1Department of Laboratory Medicine and Pathobiology, University ofToronto, 1 King's College Circle, Toronto, ON M5S 1A8, Canada. 2GeneticPathology Evaluation Centre, Department of Pathology and LaboratoryMedicine, University of British Columbia, 2660 Oak Street, Vancouver, BC V6H3Z6, Canada.Published:References1. Martin M, Brase JC, Calvo L, Krappmann K, Ruiz-Borrego M, Fisch K, Ruiz A,Weber KE, Munarriz B, Petry C, Rodriguez CA, Kronenwett R, Crespo C, Alba E,Carrasco E, Casas M, Caballero R, Rodriguez-Lescure A: Clinical validation ofthe EndoPredict test in node-positive chemotherapy-treated ER+/HER2−breast cancer patients: results from the GEICAM/9906 trial. Breast CancerRes 2014, 16:R38.2. Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF, Dietze O, Greil R,Jelen A, Sevelda P, Freibauer C, Müller V, Jänicke F, Schmidt M, Kölbl H,Rody A, Kaufmann M, Schroth W, Brauch H, Schwab M, Fritz P, Weber KE,Feder IS, Hennig G, Kronenwett R, Gehrmann M, Gnant M, EP Investigators:A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional07 Jul 2014clinical risk factors. Clin Cancer Res 2011, 17:6012–6020.3. Simon RM, Paik S, Hayes DF: Use of archived specimens in evaluation ofprognostic and predictive biomarkers. J Natl Cancer Inst 2009, 101:1446–1452.Kos and Nielsen Breast Cancer Research Page 5 of 62014, 16:103http://breast-cancer-research.com/content/16/4/1034. Dubsky P, Brase JC, Jakesz R, Rudas M, Singer CF, Greil R, Dietze O, Luisser I,Klug E, Sedivy R, Bachner M, Mayr D, Schmidt M, Gehrmann MC, Petry C,Weber KE, Fisch K, Kronenwett R, Gnant M, Filipits M, Austrian Breast andColorectal Cancer Study Group (ABCSG): The EndoPredict score providesprognostic information on late distant metastases in ER+/HER2− breastcancer patients. Br J Cancer 2013, 109:2959–2964.5. Gray RG, Rea D, Handley K, Bowden SJ, Perry P, Earl HM, Poole CJ, Bates T,Chetiyawardana S, Dewar JA, Fernando IN, Grieve R, Nicoll J, Rayter Z,Robinson A, Salman A, Yarnold J, Bathers S, Marshall A, Lee M, aTTomCollaborative Group: aTTom: long-term effects of continuing adjuvanttamoxifen to 10 years versus stopping at 5 years in 6,953 women withearly breast cancer. J Clin Oncol 2013, 31:5.6. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M,Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R,Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H,Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O,Pernas F, Petruzelka L, Pienkowski T, et al: Adjuvant Tamoxifen: LongerAgainst Shorter (ATLAS) Collaborative Group. Long-term effects ofcontinuing adjuvant tamoxifen to 10 years versus stopping at 5 yearsafter diagnosis of oestrogen receptor-positive breast cancer: ATLAS, arandomised trial. Lancet 2013, 381:805–816.7. Ioannidis JP: Is molecular profiling ready for use in clinical decisionmaking? Oncologist 2007, 12:301–311.8. Vant Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL,van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM,Roberts C, Linsley PS, Bernards R, Friend SH: Gene expressionprofiling predicts clinical outcome of breast cancer. Nature 2002,415:530–536.9. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG,Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N:A multigene assay to predict recurrence of tamoxifen-treated, node-negativebreast cancer. N Engl J Med 2004, 351:2817–2826.10. Sestak I, Dowsett M, Zabaglo L, Lopez-Knowles E, Ferree S, Cowens JW,Cuzick J: Factors predicting late recurrence for estrogen receptor-positivebreast cancer. J Natl Cancer Inst 2013, 105:1504–1511.11. Ma XJ, Salunga R, Dahiya S, Wang W, Carney E, Durbecq V, Harris A, Goss P,Sotiriou C, Erlander M, Sgroi D: A five-gene molecular grade index andHOXB13:IL17BR are complementary prognostic factors in early stagebreast cancer. Clin Cancer Res 2008, 14:2601–2608.12. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S,Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS,Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS: Supervisedrisk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009,27:1160–1167.13. Sgroi DC, Sestak I, Cuzick J, Zhang Y, Schnabel CA, Schroeder B, Erlander MG,Dunbier A, Sidhu K, Lopez-Knowles E, Goss PE, Dowsett M: Prediction of latedistant recurrence in patients with oestrogen-receptor-positive breastcancer: a prospective comparison of the breast-cancer index (BCI)assay, 21-gene recurrence score, and IHC4 in the TransATAC studypopulation. Lancet Oncol 2013, 14:1067–1076.14. Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, Zabaglo L, Mallon E,Green AR, Ellis IO, Howell A, Buzdar AU, Forbes JF: Prognostic value of acombined estrogen receptor, progesterone receptor, Ki-67, and humanepidermal growth factor receptor 2 immunohistochemical score andcomparison with the Genomic Health recurrence score in early breastcancer. J Clin Oncol 2011, 29:4273–4278.15. Ross DT, Kim CY, Tang G, Bohn OL, Beck RA, Ring BZ, Seitz RS, Paik S,Costantino JP, Wolmark N: Chemosensitivity and stratification by a fivemonoclonal antibody immunohistochemistry test in the NSABP B14 andB20 trials. Clin Cancer Res 2008, 14:6602–6609.16. Polley MY, Leung SC, McShane LM, Gao D, Hugh JC, Mastropasqua MG,Viale G, Zabaglo LA, Penault-Llorca F, Bartlett JM, Gown AM, Symmans WF,Piper T, Mehl E, Enos RA, Hayes DF, Dowsett M, Nielsen TO, InternationalKi67 in Breast Cancer Working Group of the Breast International Group andNorth American Breast Cancer Group: An international Ki67 reproducibilitystudy. J Natl Cancer Inst 2013, 105:1897–1906.17. Zhang Y, Schnabel CA, Schroeder BE, Jerevall PL, Jankowitz RC,Fornander T, Stål O, Brufsky AM, Sgroi D, Erlander MG: Breast cancerindex identifies early-stage estrogen receptor-positive breast cancerpatients at risk for early- and late-distant recurrence. Clin Cancer Res2013, 19:4196–4205.18. Denkert C, Kronenwett R, Schlake W, Bohmann K, Penzel R, Weber KE, Höfler H,Lehmann U, Schirmacher P, Specht K, Rudas M, Kreipe HH, Schraml P, SchlakeG, Bago-Horvath Z, Tiecke F, Varga Z, Moch H, Schmidt M, Prinzler J, KerjaschkiD, Sinn BV, Müller BM, Filipits M, Petry C, Dietel M: Decentral gene expressionanalysis for ER+/Her2- breast cancer: results of a proficiency testingprogram for the EndoPredict assay. Virchows Arch 2012, 460:251–259.19. Kronenwett R, Bohmann K, Prinzler J, Sinn BV, Haufe F, Roth C, Averdick M,Ropers T, Windbergs C, Brase JC, Weber KE, Fisch K, Müller BM, Schmidt M,Filipits M, Dubsky P, Petry C, Dietel M, Denkert C: Decentral gene expressionanalysis: analytical validation of the Endopredict genomic multianalytebreast cancer prognosis test. BMC Cancer 2012, 12:456.20. Christiansen J, Bartlett JMS, Gustavson M, Rimm D, Robson T, Van De Velde CJH,Hasenburg A, Kieback DG, Putter H, Markopoulos C, Dirix LY, SeynaeveCM, Rea D: Validation of IHC4 algorithms for prediction of risk ofrecurrence in early breast cancer using both conventional andquantitative IHC approaches. J Clin Oncol 2012, 30:517.21. Cronin M, Sangli C, Liu ML, Pho M, Dutta D, Nguyen A, Jeong J, Wu J,Langone KC, Watson D: Analytical validation of the Oncotype DXgenomic diagnostic test for recurrence prognosis and therapeuticresponse prediction in node-negative, estrogen receptor-positivebreast cancer. Clin Chem 2007, 53:1084–1091.22. Mamounas EP, Tang G, Paik S, Baehner FL, Liu Q, Jeong J-H, Kim S-R, Butler SM,Jamshidian F, Cherbavaz DB, Sing AP, Shak S, Julian TB, Lembersky BC,Wickerham DL, Costantino JP, Wolmark N: Association between the21-gene recurrence score (RS) and benefit from adjuvant paclitaxel(Pac) in node-positive (N+), ER-positive breast cancer patients (pts):Results from NSABP B-28. Proc SABCS 2012, Abstract:S1–S10.23. Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P,Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN,Perez EA, Pritchard KI, Shepherd L, Gralow JR, Yoshizawa C, Allred DC,Osborne CK, Hayes DF, Breast Cancer Intergroup of North America:Prognostic and predictive value of the 21-gene recurrence score assay inpostmenopausal women with node-positive, oestrogen-receptor-positivebreast cancer on chemotherapy: a retrospective analysis of a randomised trial.Lancet Oncol 2010, 11:55–65.24. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Watson D, Bryant J, CostantinoJ, Wolmark N: Expression of the 21 genes in the Recurrence Score assay andtamoxifen clinical benefit in the NSABP study B-14 of node negative, estro-gen receptor positive breast cancer. J Clin Oncol 2005, 23:510.25. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D,Bryant J, Costantino JP, Geyer CE Jr, Wickerham DL, Wolmark N: Geneexpression and benefit of chemotherapy in women with node-negative,estrogen receptor-positive breast cancer. J Clin Oncol 2006, 24:3726–3734.26. Cheang MC, Voduc KD, Tu D, Jiang S, Leung S, Chia SK, Shepherd LE, Levine MN,Pritchard KI, Davies S, Stijleman IJ, Davis C, Ebbert MT, Parker JS, Ellis MJ,Bernard PS, Perou CM, Nielsen TO: Responsiveness of intrinsic subtypesto adjuvant anthracycline substitution in the NCIC.CTG MA.5randomized trial. Clin Cancer Res 2012, 18:2402–2412.27. Chia SK, Bramwell VH, Tu D, Shepherd LE, Jiang S, Vickery T, Mardis E, Leung S,Ung K, Pritchard KI, Parker JS, Bernard PS, Perou CM, Ellis MJ, Nielsen TO:A 50-gene intrinsic subtype classifier for prognosis and prediction ofbenefit from adjuvant tamoxifen. Clin Cancer Res 2012, 18:4465–4472.28. Bastien RR, Rodríguez-Lescure Á, Ebbert MT, Prat A, Munárriz B, Rowe L,Miller P, Ruiz-Borrego M, Anderson D, Lyons B, Álvarez I, Dowell T, Wall D,Seguí MÁ, Barley L, Boucher KM, Alba E, Pappas L, Davis CA, Aranda I,Fauron C, Stijleman IJ, Palacios J, Antón A, Carrasco E, Caballero R, Ellis MJ,Nielsen TO, Perou CM, Astill M, Bernard PS, Martín M: PAM50 breast cancersubtyping by RT-qPCR and concordance with standard clinical molecularmarkers. BMC Med Genomics 2012, 5:44.29. Prat A, Bianchini G, Thomas M, Belousov A, Cheang MC, Koehler A, Gómez P,Semiglazov V, Eiermann W, Tjulandin S, Byakhow M, Bermejo B, Zambetti M,Vazquez F, Gianni L, Baselga J: Research-based PAM50 subtypepredictor identifies higher responses and improved survivaloutcomes in HER2-positive breast cancer in the NOAH study.Clin Cancer Res 2014, 20:511–521.30. Martín M, Prat A, Rodríguez-Lescure A, Caballero R, Ebbert MT, Munárriz B,Ruiz- Borrego M, Bastien RR, Crespo C, Davis C, Rodríguez CA, López-Vega JM,Furió V, García AM, Casas M, Ellis MJ, Berry DA, Pitcher BN, Harris L, Ruiz A,Winer E, Hudis C, Stijleman IJ, Tuck DP, Carrasco E, Perou CM, Bernard PS:PAM50 proliferation score as a predictor of weekly paclitaxel benefit inbreast cancer. Breast Cancer Res Treat 2013, 138:457–466.31. Nielsen T, Wallden B, Schaper C, Ferree S, Liu S, Gao D, Barry G, Dowidar N,Maysuria M, Storhoff J: Analytical validation of the PAM50-based ProsignaBreast Cancer Prognostic Gene Signature Assay and nCounter AnalysisSystem using formalin-fixed paraffin-embedded breast tumor specimens.BMC Cancer 2014, 14:177.32. Dowsett M, Sestak I, Lopez-Knowles E, Sidhu K, Dunbier AK, Cowens JW,Ferree S, Storhoff J, Schaper C, Cuzick J: Comparison of PAM50 risk ofrecurrence score with oncotype DX and IHC4 for predicting risk of distantrecurrence after endocrine therapy. J Clin Oncol 2013, 31:2783–2790.33. Filipits M, Nielsen TO, Rudas M, Greil R, Stöger H, Jakesz R, Bago-Horvath Z,Dietze O, Regitnig P, Gruber-Rossipal C, Müller-Holzner E, Singer CF,Mlineritsch B, Dubsky P, Bauernhofer T, Hubalek M, Knauer M, Trapl H,Fesl C, Schaper C, Ferree S, Liu S, Cowens JW, Gnant M, Austrian Breastand Colorectal Cancer Study Group: The PAM50 risk-of-recurrencescore predicts risk for late distant recurrence after endocrine therapyin postmenopausal women with endocrine-responsive early breastcancer. Clin Cancer Res 2014, 20:1298–1305.Cite this article as: Kos and Nielsen: Developing a new generation ofbreast cancer clinical gene expression tests.Breast Cancer ResearchKos and Nielsen Breast Cancer Research Page 6 of 610.1186/bcr36882014, 16:1032014, 16:103http://breast-cancer-research.com/content/16/4/103


Citation Scheme:


Citations by CSL (citeproc-js)

Usage Statistics



Customize your widget with the following options, then copy and paste the code below into the HTML of your page to embed this item in your website.
                            <div id="ubcOpenCollectionsWidgetDisplay">
                            <script id="ubcOpenCollectionsWidget"
                            async >
IIIF logo Our image viewer uses the IIIF 2.0 standard. To load this item in other compatible viewers, use this url:


Related Items